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Background: Missing outcome data is a threat to the validity of treatment effect estimates in randomized controlled
trials. We aimed to evaluate the extent, handling, and sensitivity analysis of missing data and intention-to-treat (ITT)
analysis of randomized controlled trials (RCTs) in top tier medical journals, and compare our findings with previous
reviews related to missing data and ITT in RCTs.
Methods: Review of RCTs published between July and December 2013 in the BMJ, JAMA, Lancet, and New England
Journal of Medicine, excluding cluster randomized trials and trials whose primary outcome was survival.
Results: Of the 77 identified eligible articles, 73 (95%) reported some missing outcome data. The median percentage of
participants with a missing outcome was 9% (range 0 – 70%). The most commonly used method to handle missing
data in the primary analysis was complete case analysis (33, 45%), while 20 (27%) performed simple imputation, 15
(19%) used model based methods, and 6 (8%) used multiple imputation. 27 (35%) trials with missing data reported a
sensitivity analysis. However, most did not alter the assumptions of missing data from the primary analysis. Reports of
ITT or modified ITT were found in 52 (85%) trials, with 21 (40%) of them including all randomized participants. A
comparison to a review of trials reported in 2001 showed that missing data rates and approaches are similar, but the
use of the term ITT has increased, as has the report of sensitivity analysis.
Conclusions: Missing outcome data continues to be a common problem in RCTs. Definitions of the ITT approach
remain inconsistent across trials. A large gap is apparent between statistical methods research related to missing data
and use of these methods in application settings, including RCTs in top medical journals.
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While randomized controlled trials are considered to be
the gold standard of intervention research in the biomed-
ical setting, their validity can be threatened by missing
outcome data. Participants with missing data are often a
non-random subset of the sample, increasing the risk of
biased estimates of treatment effects. The intention to
treat (ITT) principle, in short, “analyze as randomized”, is
recognized as an important protection against bias by pre-
serving the benefits of randomisation–namely balancing
both known and unknown factors and eliminating selec-
tion bias [1,2]. When outcome data are missing, however,
a true ITT analysis can be difficult or impossible to
achieve, and researchers must make assumptions, some of* Correspondence: melaniebell@email.arizona.edu
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unless otherwise stated.which may be strong and unverifiable [3,4]. In the pres-
ence of incomplete data therefore, it is imperative to per-
form sensitivity analyses, which examine the robustness of
the results to assumptions made in the primary analysis
[5-8].
Missing data can reduce the power and efficiency of a
study but, unfortunately, can also lead to biased results
[5-7]. For example, if patients experiencing high toxicity
are more likely to drop out of the trial, quality of life is
likely to be overestimated and toxicity underestimated.
Missing data and statistical approaches for handling
them have been an active area of research and the fol-
lowing definitions are commonly used [9]. If missingness
of the outcome of interest is unrelated to observed or
unobserved patient data, the missing data are termed
missing completely at random (MCAR): a strong as-
sumption. If data are MCAR, analyzing only those with. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in some loss of efficiency but unbiased estimation [5-7]. If
after taking observed data into account there are no sys-
tematic differences between participants with complete
data as compared to those with missing data , data are con-
sidered to be missing at random (MAR). Multiple imput-
ation [10] and model-based approaches, such as mixed
models [11] and weighted generalized estimating equations
(GEE) [12] for repeatedly measured outcomes, based on all
observed data can be valid and unbiased methods for
MAR data, as long as the models are specified correctly .
Missing outcomes are termed missing not at random
(MNAR) if systematic differences between dropouts and
completers persist even after taking observed data into ac-
count. The once popular simple imputation approach of
replacing missing data with the last observation carried for-
ward (LOCF) (for longitudinal outcome data) is not neces-
sarily valid under any of these missingness assumptions
[13,14]. Sensitivity analyses should be performed under dif-
ferent assumptions than the primary analysis for example,
if the primary analysis makes a MCAR assumption, the
sensitivity analyses should assume MAR or MNAR.
The statistical literature is rich with methods for hand-
ling incomplete data, including approaches for sensitivity
analysis and MNAR data. Guidelines for handling missing
data have been published in journals such as the Journal of
Clinical Oncology [15], the BMJ [4,16,17] and the New
England Journal of Medicine [18]. The widely adopted
CONSORT statement includes a set of checklists on ITT
and missing data [19]. Researchers in the field of missing
data, including the Panel on Handling Missing Data in
Clinical Trials commissioned recently by the National
Research Council, have made calls for the use of improved
methods for handling missing data including sensitivity
analyses, and for more rigorous approaches to ITT analysis
when outcome data are missing [4-7,16,20].
Reviews of missing data and ITT in RCTs published in
top medical journals for the years 1997, 2001, 2002 and
2005-2006 have been carried out [1,2,21,22]. These reviews
concluded that missing outcome data in RCTs are wide-
spread; poor handling of missing data is the norm; the
term ITT is common but inconsistently used; and sensitiv-
ity analyses are rarely (if ever) reported. With the recent
guidelines and exhortations to more appropriately handle
missing data (including planning and prevention), we hy-
pothesized that the amount of missing data would have de-
creased and current approaches would have improved. The
aims of this study, therefore, were to identify, in RCTs pub-
lished in the top medical journals, the proportion of trials:
1. with missing data and their handling of missing data;
2. reporting sensitivity analyses regarding missing data;
and
3. reporting an intention to treat analysis.Secondary aims included assessing indicators of plan-
ning for and prevention of, missing outcome data, and
to compare current approaches with those reported in
the previous reviews.
Methods
We performed a PubMed search of randomized controlled
trials published in four top medical journals: the British
Medical Journal (BMJ); Journal of the American Medical
Association (JAMA); The Lancet; and New England Jour-
nal of Medicine (NEJM) between July and December 2013.
Cluster randomized trials and trials whose primary out-
comes were survival were excluded because 1) the statis-
tical issues for these are different to those in individually
randomized and for non-survival outcomes and 2) we
wanted to compare our results to a previous review (see
below). The search strategy included searching for studies
in each journal whose publication type was classified as
“randomized controlled trials”. We examined each paper
collected from the initial search and identified relevant
studies based on study exclusion criteria.
Content assessment
All articles were assessed by one reviewer (MF) using a
standardized form, and 15% of the studies were randomly
selected to be independently assessed by a second and
third reviewer. We calculated kappa statistics to evaluate
inter-rater reliability for methods used to handle missing
data in primary analysis, whether an intention-to-treat
analysis was performed, and sensitivity analysis. All dis-
agreements were resolved by consensus.
Extent and handling of missing data
For each article we determined the magnitude of missing
data and method(s) for handling missing data in the princi-
pal analysis. We defined the number of subjects per trial as
the number of subjects randomized. The proportion with a
missing outcome was computed as the number of subjects
with a missing outcome divided by the total number of
subjects randomized. The principal analysis was defined as
the main analysis performed on the primary outcome.
When more than one primary outcome was reported in
the trial, we used the outcome that appeared first in the
methods section. For primary outcome measurements
monitored repeatedly, we used the final follow-up time
point to calculate the missing rate, unless a preceding time
point was specified. We identified the statistical method
used to handle missing data in the principal analysis and
classified these as complete case, simple imputation (such
as last or worst observation carried forward), multiple im-
putation or model based (for example, mixed models or
generalized estimating equations). Complete case was de-
fined as using only individuals who had complete primary
outcome data for the stated primary analysis. To assess
Table 1 General characteristics of the 77 randomized













How often outcome was collected
Single 16 (21)
Repeated 61 (79)
How outcome was treated in the primary analysis
Single 63 (82)
Repeated 14 (18)
Reported CONSORT flow diagram 76 (99)
Reported primary analysis was intention-to-treat or
modified intention-to-treat
66 (86)
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was made of attempts to avoid missing data, whether sam-
ple size calculations accounted for missing data, and by
how much observed and expected attrition rates differed.
Sensitivity analysis for missing data
We assessed method(s) to deal with missing data in any
sensitivity analysis and calculated the proportion of trials
that reported carrying out a sensitivity analysis. We defined
sensitivity analysis as any alternative technique performed
to further investigate the effects of missing outcome data
on primary results.
Intention-to-treat analysis
We determined the proportion of trials that reported an
ITT or modified ITT analysis, and verified whether all ran-
domized subjects were analyzed and how missing data
were handled if any.
Comparison of reviews on missing data
We compared our findings with previous reviews of
missing data and ITT in RCTs. For each review we re-
ported, if possible, the number of trials: included in the
review, with missing data, reporting sensitivity analysis,
reporting ITT, and missing data approaches. We aimed
to compare our results directly to Wood et al, [16] to as-
sess whether changes have occurred since their 2004
paper on RCTs published in 2001. We therefore used
similar definitions, inclusion criteria and collected data
in a similar fashion. We used chi-square tests for com-
parisons. Other reviews were compared qualitatively.
Results
Our search identified 148 randomized controlled trials
published within the six-month period. A total of 71 trials
were excluded (19 were cluster randomized controlled tri-
als, 52 had a primary outcome as time to event), leaving
77 articles to review. Inter-rater agreement for methods
used to handle missing data in primary analysis, intention-
to-treat, and sensitivity analysis were 0.72, 0.94, and 0.78,
respectively, showing “substantial” to “near perfect” agree-
ment, according to Landis and Koch [23]. Table 1 shows
the general characteristics of the included trials. Together,
the median number of subjects randomized was 368, with
a range of 13 – 53,450. A list of included studies can be
found in Additional file 1.
Extent and handling of missing data
Seventy-three (95%) trials reported some missing outcome
data. The median percentage of patients with a missing
outcome was 9%, with a range of 0 – 70%. Sixty-six trials
reported reasons why outcomes were missing with reasons
ranging from simply stating that patients were lost to
follow-up to very specific explanations. The majority oftrials reported these details in their CONSORT flow dia-
gram [19].
Complete case analysis was the most common method
to handle missing data (33, 45%). Twenty (27%) trials
used simple imputation methods. Three (5%) used linear
interpolation, eight (11%) used worst-case imputation,
nine (12%) used last observation carried forward. Six
(8%) trials performed multiple imputation. Fifteen (19%)
trials used model based methods: 11 (15%) used mixed
models and three (4%) used un-weighted generalized es-
timating equations (Table 2). Thus, a MAR assumption
for the primary analysis was made in 17 (23%) of the tri-
als with missing data.
Of the trials reporting more than 10% missing data, 13
(36%) used complete case, 13 (36%) used simple imput-
ation, 3 (8%) used multiple imputation, and 7 (19%) used
model based methods. Of the trials reporting less than
10% missing data, 20 (54%) used complete case, 7 (19%)
used simple imputation, 3 (8%) used multiple imput-
ation, and 7 (19%) used model based methods.
Sixty-six (86%) trials presented a sample size calculation,
with 38 of them accounting for missing data in the calcula-
tion by inflating the sample size by one minus the expected
attrition rate. The mean absolute difference in the actual
attrition rate and the expected was 8% with a range of 0.3–
31%. Two trials accounting for missing data in the sample
Table 2 Handling of missing data in primary analysis
among 73 trials who reported missing outcome data
N (%)1
Proportion of patients with missing outcome1
No missing data 4 (5)
0 – 1% 2 (3)
1 – 5% 11 (14)
5 – 10% 24 (31)
> 10% 36 (47)
Reported number of patients with missing outcomes
by randomized treatment arm
71 (97)
Reported reasons why missing 66 (90)




Complete case 33 (45)
Simple imputation
Linear interpolation 3 (5)
Worst-case 8 (11)
LOCF 9 (12)
Multiple imputation 6 (8)
Model based
GEE (un-weighted) 3 (4)
Mixed model/hierarchical/multilevel 11 (15)
1The denominator for the proportion of patients with missing outcome is 77;
the other denominators are 73 (the number of studies with any missing data).
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estimated higher attrition rates than observed, while 28%
estimated lower attrition rates than observed.
Attempts to avoid missing data before and during the
trial were mentioned in 26 trials. The median percentage
of missing data for those who mentioned attempts to
avoid missing data was 12%, with a range of 2–56%. The
median percentage of missing data for those who did
not mention attempts to avoid missing data was 9%,
with a range of 0.6 – 70%.
Seventy-one (97%) trials reported the number of pa-
tients with missing outcome by treatment arm. Nine trials
reported comparisons of baseline characteristics between
patients with observed and missing outcomes. Six of them
reported a significant difference.
Sensitivity analysis for missing data
Twenty-seven trials (35%) reported performing a sensi-
tivity analysis with respect to missing data (Table 3). Of
these, ten (37%) trials used multiple imputation in the
sensitivity analysis. Six (22%) performed a complete case
analysis. Four (15%) trials carried out simple imputation:
two performed worst-case imputation and one imputed
with baseline value. One trial performed both completecase analysis and LOCF. One trial performed worst-case
imputation, LOCF, and multiple imputation. Two trials
carried out adjustments using auxiliary data. One trial
used un-weighted GEE and two trials used mixed models.
Two trials reported that they performed a sensitivity ana-
lysis, but methods were unclear.
In total, 11 made a MCAR assumption for the sensitivity
analysis, and 15 made a MAR assumption. Only 10 weak-
ened the missingness assumption of the primary analysis
to perform their sensitivity analysis, by using a MCAR as-
sumption for the primary followed by a MAR assumption
in the sensitivity. No researchers used MNAR models. Of
the 36 trials reporting more than 10% missing data, 16
(44%) performed a sensitivity analysis: 4 used complete
case, 2 used simple imputation, 1 used simple and multiple
imputation, 6 used multiple imputation, 2 made adjust-
ments using auxiliary data, and 1 approach was unclear. Of
the 41 trials reporting less than 10% missing data, 11 (27%)
performed a sensitivity analysis: 2 used complete case, 1
used complete case and simple imputation, 1 used simple
imputation, 3 used multiple imputation, 3 used model
based methods, and 1 was unclear.
Intention-to-treat analysis
Fifty-two reported the use of ITT and 14 reported the use
of modified ITT for their primary analysis. Definitions of
ITT and modified ITT differed across trials. Of the articles
that reported ITT or modified ITT analysis, 21 (40%) in-
cluded all randomized subjects in the primary analysis. Of
the articles that reported ITT or modified ITT analysis, 62
(94%) had missing data. Of the trials with missing data, 48
(66%) reported ITT analysis and 14 (19%) reported modi-
fied ITT analysis.
Comparison of reviews on missing data
Of the five reviews that we considered, including our own,
missing data rates were fairly similar, ranging from 61–
95%. Use of complete case analysis and simple imputation
were consistent across reviews, ranging from 45–65% and
17–27%, respectively. Recently, there has been an increase
in application of multiple imputation and model based
methods for missing data in primary analyses. The num-
ber of papers reporting sensitivity analysis for missing data
(1–37%) and ITT analysis (48–85%) have both increased
across time. See Table 4.
In comparison to Wood et al.’s [22] review of RCTs
from 2001, trials reporting missing data were similar:
89% versus 95% (95% confidence interval (CI) for differ-
ence -3% to 15%; P = 0.18). The percentage of papers
with 10% or more missing data was also similar, at 51%
versus 47% (95% CI for difference -12% to 20%; P =
0.63). Of those that reported missing data, trials that
used complete case analysis decreased from 65% to 45%
(95% CI for difference -36% to -3%; P = 0.02). The
Table 3 Methods for handling missing data in sensitivity analysis in 27 trials
Sensitivity method Assumption Primary analysis Assumption N Total N (%)
Complete case MCAR Simple imputation MCAR 3 6 (22)
MI MAR 2
Mixed Model MAR 1
Simple imputation1 MCAR GEE MCAR 1 4 (15)
MI MAR 1
Mixed model MAR 2
GEE (un-weighted) MCAR Complete case MCAR 1 1 (4)
MI2 MAR Complete case MCAR 6 10 (37)
Simple imputation MCAR 1
GEE MCAR 1
Mixed model MAR 2
Mixed model MAR Complete case MCAR 2 2 (7)
Adjustment using auxiliary data MAR Mixed model MAR 2 2 (7)
Unclear Complete case MCAR 1 2 (7)
Simple imputation MCAR 1
1One trial also performed complete case analysis.
2One trial also performed simple imputation.
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22% as compared to 27% (95% CI for difference -9% to
19%; P = 0.49). The use of multiple imputation or model
based methods increased from 10% to 27% (95% CI for
difference 5% to 30%; P = 0.01). Mentions of attempts to
avoid missing data was similar, at 35% compared to 29%
(95% CI for difference -46% to -58%; P = 0.83). Sensitiv-
ity analysis for missing data increased from 21% to 37%
(95% CI for difference 1% to 31%; P = 0.04). Reports of
ITT or modified ITT analysis increased from 41% to
85% (95% CI for difference 29% to 59%; P <0.0001).
Discussion
Summary
Our review of 77 RCTs published in the top medical jour-
nals found that 95% of trials reported some missing out-
come data, with a median of 9%, and up to 70%. Complete
case analysis was the most common way of handling miss-
ing data in the primary analysis (45%), followed by simple
imputation (27%), model based methods (mixed models
and un-weighted generalized estimating equations) (19%)
and multiple imputation (8%). Sensitivity analyses were
performed in 35% of the trials, but most (63%) did not
weaken the assumptions regarding missing data from their
primary analysis. An ITT or modified ITT was reported in
85% of the trials. Most reports included a sample size cal-
culation (86%), and 58% of these inflated the sample size to
account for expected attrition. These calculations tended
to be conservative, with 72% estimating higher dropout
than observed with a difference of 8%, and ranging up to
30% higher.Relation to other literature
The amount of missing data appears to have remained
fairly constant over time, as does the proportion of trials
that mentioned attempts to avoid missing data. While it
is possible that those trials that did not report preven-
tion attempts did, in fact, employ them, it may be that
researchers need to give more consideration to missing
data during trial design and conduct.
The use of methods with the strong assumption that
data are missing completely at random (complete case
analysis, simple imputation and un-weighted GEE) has
remained popular: 85% in the current review as com-
pared to 89% in the 2001 review. This is in direct con-
trast to recommendations put forth by leaders in the
field, including the National Research Council’s Commit-
tee on National Statistics (CNSTAT) Panel on Handling
Missing Data in Clinical Trials which recommends a pri-
mary analysis that assumes data are missing at random,
followed by sensitivity analyses which weaken this as-
sumption and allows for data not missing at random
[7,18]. White et al. [4] suggest a four part strategy: 1) at-
tempt to follow up all subjects; 2) carry out a primary
analysis of all observed data that are valid under a plaus-
ible assumption; 3) perform sensitivity analyses to explore
the effect of departures from the primary assumption; and
4) account for all randomized participants in at least one
of the analyses. This approach was utilized in the analysis
of an alcohol screening and brief intervention study [24].
It was discouraging that sensitivity analyses which contra-
dict the assumptions of the primary analyses remain
so rare.
Table 4 Reviews on missing data and ITT in the BMJ, JAMA, NEJM and the Lancet1





Number (%) of papers













1997 All RCTs 249 89/119 (75) 29/119 (24) Complete case 44 (49) 1 (1) 119/249 (48)
Simple imputation 15 (17)
Multiple imputation 0




July-Dec, 2001 All RCTs with non-survival
outcomes
71 63/71 (89) 36/71 (51) Complete case 41 (65) 13 (21) 26/63 (41)
Simple imputation 14 (22)
Multiple imputation 1 (2)




2002 Sample of RCTs1 403 152/249 (61) 52/249 (21) Complete case 89 (59) Not reported 249/403 (62)
Simple imputation 32 (21) 201/283 (71)5





2005-2006 Random sample of RCTs
with Quality of life
outcomes
61 55/61 (90) 22/61 (36) Complete case 30 (55) 6 (11) Not reported
Simple imputation 11 (20)
Multiple imputation 1 (2)




July-Dec, 2013 All RCTS with non-survival
outcomes
77 73/77 (95) 36/77 (47) Complete case 33 (45) 27 (37) 62/73 (85)
Simple imputation 20 (27)
Multiple imputation 6 (8)
Model based 14 (19)
1Gravel et al. reported on 10 journals, including the BMJ, JAMA, NEJM and the Lancet.
2Denominator is the number of trials included except for Hollis et al. and Gravel et al., where denominators are the number of papers reporting ITT.
3Denominator is the number of papers with missing data.
4Denominator is the number of papers with missing data except for Hollis et al. and Gravel et al. where denominators are the number of trials included in the review.
5Sub-analysis of RCTs from the four journals (BMJ, JAMA, NEJM and the Lancet) out of the 10 journals included in Gravel’s review.
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generalized estimating equation (GEE) methods and mul-
tiple imputation, in part because auxiliary data associated
with missingness can be incorporated into the analysis [18].
However, none of the RCTs in our review used weighted
GEEs, and only 8 used MI for the primary analysis. While
the number of trials reporting sensitivity analyses appear to
have increased over time, from 1% in 1997, 21% in 2001,
and up to 37% in our review, none of the studies reported
using MNAR models, or appeared to follow the Panel’s
guidelines for sensitivity analyses. Perhaps the reluctance to
use more sophisticated approaches is due to a lack of
knowledge or experience on the parts of applied re-
searchers and/or biostatisticians. Perhaps it is due to
the time lag between reports of methods and software
to implement them.
Reports of ITT or modified ITT analysis have increased
substantially over time, from 48% in 1997, 41% in 2001,
71% in 2007, to 85% in 2013. However, we found, as others
have [1,2], that these terms are used inconsistently: only
40% actually included all randomized participants in the
primary analysis. White et al. [20] call for at least one ana-
lysis (primary or sensitivity) to include all participants.
This lack of consistent definition (even amongst method-
ologists [25]) and clarity regarding who was included in
the analysis has led the CONSORT statement’s authors to
remove the ITT request in their 2010 update (over the ori-
ginal 2001 statement) [19].
Many trials had repeated measurements, (79%) but only
14 of these used all the measurements in the primary ana-
lysis, often resulting in a strong MCAR assumption. Using
all outcome data, even if the primary interest is in a spe-
cific time point, can reduce some or all of the bias due to
data which are missing non-randomly. For example, Bell
and Fairclough use several methods to analyze quality of
life measured at four time points in an RCT with substan-
tial missing data. A t-test comparing the two arms at the
4th timepoint found a treatment effect of -0.4; a contrast
from a mixed model estimated the effect to be -8.0 [5].
Simulation studies have demonstrated the bias that can
occur when a MCAR assumption is made for data which
are MAR [17,26]. Approaches which use all repeated mea-
sures data and are valid for MAR data include multiple
imputation, mixed models, inverse probability weighted
GEEs, and Bayesian analysis [5-7].
Strengths and limitations
A strength of our review is the inclusion of other reviews
to assess possible time trends. In particular, we followed
Wood and colleagues [22] methods and definitions in
order to make direct comparisons between 2001 and
2013. A limitation is the difficulty in making comparisons
with the other reviews, due to different inclusion criteria.
For example, inclusion of survival outcomes may reducemissing data rates, as participants who drop out are often
considered censored. Different definitions may also hinder
comparisons. For example, the rate of missing data when
measurements are taken repeatedly could be: 1) the num-
ber of patients with any missing primary outcome data di-
vided by the total number of patients randomized; or 2)
the number of missing assessments divided by the total
number of assessments. We chose the former, in line with
Wood et al. [22] Another limitation is that we focused on
the top 4 medical journals. It is likely that trial reports
appearing in these journals have higher standards of con-
duct and reporting, so that this review may underestimate
the extent of missing data and overestimate the use of sen-
sitivity analyses.Recommendations and conclusion
We have several recommendations. First, missing data
should be considered at each stage of a trial: design,
conduct, analysis, and reporting. Prevention is the best
way to handle missing data, so more effort needs to be
put into missing data at the design and conduct stage.
The CNSTAT report [7], and it’s synopsis [18] discuss
several approaches. Second, we recommend that in tri-
als with repeated measurements, all data should be
used in an analysis that makes a plausible assumption
about missing data. Usually this will be a MAR as-
sumption. Third, sensitivity analyses that weaken the
assumptions about missing data should be carried out
and reported. For example, if the primary analysis uses
a MAR assumption, the sensitivity analysis should as-
sume MNAR.
There appears to be a large gap in translation between
statistical methods research and the use of these methods
in applications, such as RCTs. For example, simple imput-
ation remains popular, despite warnings from many statisti-
cians against their use, particularly LOCF [5-7,13,14,27-29].
This failure to translate persists, despite papers regard-
ing missing data, sensitivity analyses, and strategies for
intention to treat in the presence of missing data being
published in high impact medical journals [4,16-18]. More
statisticians should attempt to make their work accessible
to applied researchers, by publishing secondary papers in
appropriate applied journals showing how to make their
methods work in practice. Applied statisticians and re-
searchers should read these papers to update their skillsets
and use modern methods that increase statistical power
and in some cases reduce bias. Editors and reviewers
should demand that modern methods which use all the
data are used, at least in the sensitivity analysis.Conclusions
Applied researchers and statisticians need to improve
their handling of missing data in RCTs.
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